33,280 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 33,280 shares of the company's stock, valued at approximately $3,881,000. Lisanti Capital Growth LLC owned 0.07% of Axsome Therapeutics as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Intech Investment Management LLC boosted its stake in Axsome Therapeutics by 46.5% in the fourth quarter. Intech Investment Management LLC now owns 16,028 shares of the company's stock valued at $1,356,000 after acquiring an additional 5,087 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $14,771,000. Charles Schwab Investment Management Inc. boosted its position in Axsome Therapeutics by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company's stock valued at $27,755,000 after purchasing an additional 5,438 shares during the period. Aigen Investment Management LP acquired a new position in Axsome Therapeutics during the 4th quarter valued at approximately $395,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Axsome Therapeutics by 20.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,642 shares of the company's stock worth $4,877,000 after buying an additional 9,928 shares during the period. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Price Performance

AXSM traded down $1.42 during trading on Tuesday, reaching $102.97. The stock had a trading volume of 483,711 shares, compared to its average volume of 670,308. The stock has a 50 day moving average of $106.66 and a two-hundred day moving average of $107.39. The company has a quick ratio of 1.96, a current ratio of 2.03 and a debt-to-equity ratio of 3.48. The firm has a market capitalization of $5.07 billion, a price-to-earnings ratio of -17.85 and a beta of 0.46. Axsome Therapeutics, Inc. has a 1-year low of $72.21 and a 1-year high of $139.13.

Analysts Set New Price Targets

Several equities analysts have recently commented on AXSM shares. Jefferies Financial Group started coverage on shares of Axsome Therapeutics in a research report on Monday, April 7th. They set a "buy" rating and a $200.00 price target for the company. Robert W. Baird lifted their price objective on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the company an "outperform" rating in a research report on Tuesday, May 6th. Wells Fargo & Company reissued an "overweight" rating and set a $165.00 target price (up from $160.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 6th. Cantor Fitzgerald upgraded shares of Axsome Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Finally, Needham & Company LLC cut their price target on Axsome Therapeutics from $153.00 to $150.00 and set a "buy" rating on the stock in a report on Monday, June 9th. One equities research analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Axsome Therapeutics currently has a consensus rating of "Buy" and an average target price of $172.33.

Insider Buying and Selling

In other news, COO Mark L. Jacobson sold 25,000 shares of Axsome Therapeutics stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $110.44, for a total value of $2,761,000.00. Following the transaction, the chief operating officer owned 5,783 shares of the company's stock, valued at $638,674.52. The trade was a 81.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Mark Coleman sold 3,750 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $105.47, for a total transaction of $395,512.50. Following the completion of the sale, the director owned 50,387 shares in the company, valued at $5,314,316.89. The trade was a 6.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 93,437 shares of company stock valued at $9,834,215 over the last three months. Company insiders own 22.40% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.